Studies on Anticoagulant and Antithrombotic Effects of Recombinant Hirudin-III

AIM The purpose is to study the secretory manufacture of recombinant hirudin Ⅲ(HⅧ) and its anticoagulant and antithrombotic effects. METHODS Inferior vena cava thrombosis model in rats and A V circulation \%in vivo\% in rats were used to study recombinant hirudin Ⅲ(HⅧ)′s anticoagulant and antithrombotic effects. RESLUTS The weight of inferior vena cava thrombosis was 21.30±7.35 and 10.40±16.20 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg; the weight of thrombosis in A V circulation was 21.5±5.3 mg and 15 3±3.6 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg. CONCLUSION The antithrombotic and anticoagulant activity of recombinant hirudin Ⅲ was different from that of placebo group significantly in statistics. It could be developed to make a new antithrombotic drug.